Performance of Bioabsorbable Vascular Scaffolds (Absorb) Compared to Xience Stents - an Optical Coherence Tomography Study
Launched by RUDOLF BERGER · Nov 27, 2013
Trial Information
Current as of July 23, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria for implanting an Absorb scaffold:
- • age \< 55 years OR
- • lesion length \> 24mm OR
- • multiple lesions to be treated
About Rudolf Berger
Rudolf Berger is a clinical trial sponsor dedicated to advancing medical research and innovation through rigorous and ethical study designs. With a focus on developing groundbreaking therapies, the organization collaborates with leading researchers and institutions to conduct clinical trials that prioritize patient safety and efficacy. Leveraging a strong foundation in scientific expertise and regulatory compliance, Rudolf Berger strives to bring transformative treatments to market, addressing unmet medical needs across various therapeutic areas. Their commitment to excellence and integrity in clinical research positions them as a trusted partner in the pharmaceutical and biotechnology industries.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials